Global T Lymphocyte Activation Antigen CD80 Market Size, Share and Trends Analysis Report Forecast (2024-2031)

The global T lymphocyte activation antigen CD80 market is anticipated to grow at a significant CAGR 3.3% during the forecast period (2024-2031). CD80 is a costimulatory molecule that is known for its role in T-cell activation. It also regulates the activity of normal and malignant B cells. The major factor driving the demand for T lymphocyte activation antigen CD80 is the increasing prevalence of acute myelocytic leukemia (AML) across the globe.

According to the American Society of Clinical Oncology (ASCO), AML is uncommon and makes up about 1% of cancers. Additionally, in 2021, an estimated 20,240 people of all ages which include 11,230 men and boys and 9,010 women and girls was diagnosed with AML in the US. Furthermore, AML is the second most common type of leukemia diagnosed in adults and children, however, most cases occur in adults and makes up 31% of all adult leukemia cases. Moreover, the average age of diagnosis is 68 years, however, it can be diagnosed at any age. Hence, the increasing prevalence of AML is driving the demand for T lymphocyte activation antigen CD80 as it is used as immunotherapy by identifying neoplastic cells and sparing healthy tissue which in turn is driving the growth of the market.

Some major players in the market include Bristol-Myers Squibb Co, and KAHR Medical Ltd, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2021, AstraZeneca announced positive high-level results from the Phase III Himalaya clinical trial of Imfinzi (durvalumab) plus tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (HCC) patients. Tremelimumab is an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody.

Get Sample Copy of this Report at

https://www.omrglobal.com/request-sample/t-lymphocyte-activation-antigen-cd80-market



• Competitive Landscape- Bristol-Myers Squibb Co, and KAHR Medical Ltd, among others.



Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?



Inquire for Discount on this Report at



https://www.omrglobal.com/report-customization/t-lymphocyte-activation-antigen-cd80-market



Global T Lymphocyte Activation Antigen CD80 Market Report by Segment

By Type

• Abatacept

• Abatacept Biosimilar

• CUE-201

• KAHR-102

• Others



By Application

• Metabolic Disorders

• Autoimmune Disorders

• Acute Myelocytic Leukemia

• Others

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 780-304-0404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.